Armenian Hamster IgG Isotype Control – Purified in vivo GOLD™ Functional Grade
Armenian Hamster IgG Isotype Control – Purified in vivo GOLD™ Functional Grade
Product No.: I-140
- -
- -
- -
- -
Antibody DetailsProduct DetailsHost Species Armenian Hamster Recommended Dilution Buffer Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C Working Concentration This isotype control antibody should be used at the same concentration as the primary antibody. RRIDAB_2737537 Applications and Recommended Usage? Quality Tested by Leinco FC This isotype control antibody should be used at the same concentration as the primary antibody. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity This Armenian Hamster IgG isotype control monoclonal antibody has been tested against selected species' cells and tissues to assure minimal cross-reactivity. References & Citations1.) Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117. PubMed 2.) Oldstone, MBA. et al. (2017) Proc Natl Acad Sci U S A. 114(14): 3708–3713. PubMed 3.) Schreiber, RD. et al. (2015) PLoS One.10(5):e0128636. PubMed 4.) Diamond, MS. et al. (2017) J Virol. 91(22): e01419-17. PubMed 5.) Gubin, M. et al. (2018) Cell. 175(4):1014–1030.e19 Journal Link 6.) Czepielewski, R. et al. (2021) Immunity 54(12):2795-2811.e9 Journal Link 7.) Winkler, E. et al. (2020) Cell 182(4):901-918.e18 Journal Link Technical ProtocolsCertificate of Analysis |
Related Products
- -
- -
Prod No. | Description |
---|---|
E234 | |
E200 | |
E280 |
Formats Available
- -
- -
Prod No. | Description |
---|---|
I-905 | |
I-445 | |
I-446 | |
I-897 | |
I-898 | |
I-899 | |
I-901 | |
I-902 | |
I-903 | |
I-448 | |
I-447 | |
I-140 | |
P376 |